Stereotaxis, Abbott Ink Pact To Combine Mapping & Robotic Tech: FDA Approves Abbott's Next-Gen Abalation Catheter
Portfolio Pulse from Vandana Singh
Stereotaxis Inc (STXS) and Abbott Laboratories (ABT) have announced a global collaboration to integrate Abbott's EnSite X EP System with Stereotaxis' Robotic Magnetic Navigation systems. The integrated technologies are cleared for use in Europe, with additional regulatory clearances expected in the coming months. The FDA also approved Abbott's TactiFlex Ablation Catheter, Sensor Enabled.
May 19, 2023 | 5:23 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Abbott partners with Stereotaxis and receives FDA approval for its TactiFlex Ablation Catheter, Sensor Enabled.
The collaboration with Stereotaxis and the FDA approval of Abbott's TactiFlex Ablation Catheter will likely contribute to the company's growth and product offerings. This positive news is expected to have a short-term positive impact on ABT's stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100
POSITIVE IMPACT
Stereotaxis partners with Abbott to integrate their technologies, boosting STXS shares by 34.7%.
The partnership with Abbott, a major player in the healthcare industry, is a significant milestone for Stereotaxis. The integration of their technologies and the regulatory clearances in Europe will likely lead to increased adoption and revenue for STXS, positively impacting its stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100